Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Common Equity for 7 consecutive years, with $66.4 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 42.56% year-over-year to $66.4 million; the TTM value through Mar 2026 reached $66.4 million, down 42.56%, while the annual FY2025 figure was $74.3 million, 42.91% down from the prior year.
  • Common Equity hit $66.4 million in Q1 2026 for Barinthus Biotherapeutics, down from $74.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $254.8 million in Q2 2022 and bottomed at $66.4 million in Q1 2026.
  • Average Common Equity over 5 years is $170.0 million, with a median of $172.0 million recorded in 2024.
  • Year-over-year, Common Equity skyrocketed 579.14% in 2022 and then crashed 46.97% in 2025.
  • Barinthus Biotherapeutics' Common Equity stood at $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.41% to $130.1 million in 2024, then tumbled by 42.91% to $74.3 million in 2025, then decreased by 10.62% to $66.4 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $66.4 million, $74.3 million, and $84.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.